logo
Plus   Neg
Share
Email

Stock Alert: AutoNation Spikes On Q1 Earnings

Shares of automotive retailer AutoNation, Inc. (AN) are rising more than 5% Monday on the back of upbeat first-quarter earnings.

AutoNation said sales started strengthening in April with same-store new and used retail unit sales down 19% during the final 10 days, compared to 52% drop during the first 10 days.

For the first quarter, net loss from continuing operations for the first quarter was $232 million, or $2.58 per share, compared to net income from continuing operations of $92 million, or $1.02 per share, in the prior-year period. The company had incurred non-cash charges in the first quarter, as the result of COVID-19 related impacts to the business and market valuation.

Excluding items, earnings of $0.91 beat the average estimate of 10 analysts polled by Thomson Reuters at $0.69.

Revenue for the quarter decreased to $4.667 billion from $4.982 billion in the same quarter a year as the Covid-19 pandemic has adversely impacted the company's operations.

AutoNation stock is currently trading at $40.07. It has traded in the range of $20.59- $53.19 in the last 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT